Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
Símbolo de cotizaciónAVXL
Nombre de la empresaAnavex Life Sciences Corp
Fecha de salida a bolsaApr 13, 2006
Fundada en2004
Director ejecutivoDr. Christopher U. Missling, Ph.D.
Número de empleados42
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 13
Dirección630 5Th Avenue
CiudadNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10111
Teléfono18446893939
Sitio Webhttps://www.anavex.com
Símbolo de cotizaciónAVXL
Fecha de salida a bolsaApr 13, 2006
Fundada en2004
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos